Key terms
About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SNY news
May 16
12:37pm ET
Strong Buy Rating for Sanofi on Dupixent’s Expansion and Pipeline Potential
May 15
10:40am ET
Biotech Alert: Searches spiking for these stocks today
May 14
4:39am ET
Buy Rating for Sanofi: Strong Growth and Attractive Valuation Amidst Pipeline Optionality and Strategic Leadership
May 13
12:33pm ET
Fulcrum Therapeutics price target raised to $22 from $19 at Stifel
May 13
7:56am ET
TD Cowen Reaffirms Their Hold Rating on Sanofi (SNY)
May 13
7:23am ET
Novavax price target raised to $10 from $5 at TD Cowen
May 13
6:03am ET
Fulcrum Therapeutics, Sanofi enter collaboration and license agreement
May 13
5:28am ET
Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
May 10
12:34pm ET
BofA upgrades Novavax to Neutral on ‘best outcome’ Sanofi pact
May 10
10:56am ET
H.C. Wainwright reiterates Buy rating on Novavax after ‘landmark’ Sanofi deal
May 10
9:46am ET
NVAX Earnings: Novavax Soars After Mixed Q1, Sanofi Deal Boost
May 10
8:39am ET
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF)
May 10
5:18am ET
Novavax, Sanofi enter co-exclusive COVID-19 vaccine licensing agreement
May 09
7:58am ET
Royalty Pharma to acquire royalty interest in Sanofi’s frexalimab
May 08
10:26am ET
Pfizer agrees to settle over 10,000 Zantac cancer suits, Bloomberg reports
May 02
4:59pm ET
Sanofi’s Frexalimab Shows Promise in MS Trial
Apr 30
10:13am ET
FTC expands patent listing challenges for drugs
Apr 29
3:13pm ET
Sanofi price target raised to EUR 98 from EUR 94 at JPMorgan
Apr 26
9:45pm ET
Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)
Apr 25
2:35pm ET
DZ BANK AG Keeps Their Hold Rating on Sanofi (SNYNF)
Apr 25
12:01pm ET
Sanofi SA Starts 2024 with Strong Sales Growth
Apr 25
10:35am ET
Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)
Apr 25
6:47am ET
SNY Earnings: Sanofi Jumps on Healthy Q1 Performance
Apr 25
6:18am ET
Sanofi expects FY24 business EPS to remain relatively stable
Apr 25
6:17am ET
Sanofi reports Q1 IRFS EPS EUR 0.91, down 43.1%
Apr 23
5:32am ET
Buy Rating Affirmed for Sanofi Amid Strong Growth Prospects and Undervalued Stock
Apr 22
11:36am ET
Previously announced Zantac settlement worth $100M, Bloomber says
Apr 22
10:33am ET
Sanofi to pay $100M to settle Zantac cancer lawsuits, Bloomberg says
Apr 22
3:35am ET
UBS Keeps Their Buy Rating on Sanofi (SNYNF)
Apr 19
6:21pm ET
VGK vs. EZU: Which Is the Better European Stock ETF?
Apr 18
2:08pm ET
IGM Biosciences weakness creates ‘interesting opportunity,’ says Stifel
No recent press releases are available for SNY
SNY Financials
Key terms
Ad Feedback
SNY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SNY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
